New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.
The Food and Drug Administration (FDA) is amending its new drug and biological product regulations to allow appropriate studies in animals in certain cases to provide substantial evidence of the effectiveness of new drug and biological products used to reduce or prevent the toxicity of chemical, biological, radiological, or nuclear substances. This rule will apply when adequate and well-controlled clinical studies in humans cannot be ethically conducted and field efficacy studies are not feasible. In these situations, certain new drug and biological products that are intended to reduce or prevent serious or life-threatening conditions may be approved for marketing based on evidence of effectiveness derived from appropriate studies in animals and any additional supporting data.
D000818:Animals; D001688:Biological Products / Q000009:adverse effects; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods; D004341:Drug Evaluation / Q000941:ethics / Q000331:legislation & jurisprudence* / Q000379:methods; D004348:Drug Labeling; D064420:Drug-Related Side Effects and Adverse Reactions; D004992:Ethics, Medical; D006805:Human Experimentation / Q000941:ethics / Q000331:legislation & jurisprudence*; D006801:Humans; D004364:Pharmaceutical Preparations; D018675:Toxicity Tests / Q000941:ethics / Q000662:veterinary; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products; D004364:Pharmaceutical Preparations